Phase 3 Alzheimer's Disease Trial, TerminatedNCT01127633Sponsor: Eli Lilly and CompanyCondition: Alzheimer's Disease
Printed from Voxsanity (voxsanity.com.au) — NCT01127633 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
This trial is terminated. It is no longer accepting participants. See the expanded access section below for other pathways.
Trial results
AI generated results summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01127633) looked at a drug called solanezumab, which was being studied in people with Alzheimer's disease. A total of 723 people were assigned to receive a placebo (an inactive treatment) and 734 were assigned to receive solanezumab — 1,457 participants in all. The trial ran for around two years (104 weeks) and measured things like unwanted health events (called adverse events), changes in memory and thinking, ability to carry out everyday tasks, behaviour, and how much time caregivers spent providing care.
The reported data shows that for the primary measure — the number of participants who experienced at least one health event considered related to the study drug — 308 people in the placebo group and 299 in the solanezumab group had such an event. For serious health events of any cause, the numbers were 485 in the placebo group and 514 in the solanezumab group. On the memory and thinking scale (scored 0–90, where higher means more difficulty), both groups changed by roughly the same amount — about 17.6 points in each group. On the daily living scale (scored 0–78, where lower means more difficulty), the placebo group's score fell by about 26.8 points and the solanezumab group's fell by about 24.8 points. On the dementia severity scale (scored 0–18, higher meaning more severe), scores increased by about 5.6 points in the placebo group and 5.3 points in the solanezumab group. Behaviour scores and caregiver time data were also reported, with small numerical differences between the two groups across those measures.
These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Alzheimer's Disease Trial, Terminated
NCT01127633
TerminatedPhase 3🇦🇺 Australian site
Who may be able to join
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
You have been diagnosed with Alzheimer's Disease based on specific recognised medical guidelines
You have already completed 80 weeks of participation in one of two related previous studies (called Study LZAM or Study LZAN)
You have a trusted person (such as a family member or carer) who is in regular contact with you and is able to support you throughout the entire study
You have veins that are suitable for receiving medication through a drip (IV infusion)
You agree not to take part in any other trials testing new treatments while you are in this study
Who may not be able to join:
You are currently taking part in, or have taken part in within the last 30 days, another trial testing a new drug or device, or you are involved in other medical research that may not be compatible with this study
You met the criteria that would have required you to stop participating early at the end of Study LZAM or Study LZAN (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Australian sites
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gosford, New South Wales
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chermside, Queensland
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toowoomba, Queensland
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Box Hill, Victoria
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glen Iris, Victoria
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg Heights, Victoria
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melbourne, Victoria
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Subiaco, Western Australia
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I found the following past clinical trial relevant to my condition, and wanted to raise it with you. It is no longer recruiting, but I wanted to ask whether similar active trials exist, or whether its results are relevant to my care:
Trial: NCT01127633
Sponsor: Eli Lilly and Company
Phase: Phase 3
Status: Terminated
Condition: Alzheimer's Disease
More information: https://clinicaltrials.gov/study/NCT01127633
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
You have been diagnosed with Alzheimer's Disease based on specific recognised medical guidelines
You have already completed 80 weeks of participation in one of two related previous studies (called Study LZAM or Study LZAN)
You have a trusted person (such as a family member or carer) who is in regular contact with you and is able to support you throughout the entire study
You have veins that are suitable for receiving medication through a drip (IV infusion)
You agree not to take part in any other trials testing new treatments while you are in this study
Who may not be able to join:
You are currently taking part in, or have taken part in within the last 30 days, another trial testing a new drug or device, or you are involved in other medical research that may not be compatible with this study
You met the criteria that would have required you to stop participating early at the end of Study LZAM or Study LZAN (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇷 Argentina
🇦🇺 Australia
🇧🇷 Brazil
🇨🇦 Canada
🇫🇷 France
🇩🇪 Germany
🇮🇹 Italy
🇯🇵 Japan
🇵🇱 Poland
🇷🇺 Russia
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇹🇼 Taiwan
🇬🇧 United Kingdom
🇺🇸 United States
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Assess the Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.